Cited by 573Angiogenesis and VEGF in CancerColorectal Cancer Treatments and StudiesBreast Cancer Treatment Studies

The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.

Biomarkers of response and resistance to antiangiogenic therapy

Open access

Jain, Rakesh K., Duda, Dan G., Willett, Christopher G., Sahani, Dushyant V., Zhu, Andrew X., Loeffler, Jay S., Batchelor, Tracy T., Sorensen, A. Gregory·2009·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2009.63PMC PMC3057433

Open this paper in CoChat — free account

Abstract

No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2009.63

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citation
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citation
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,551
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K. D., Wang, M., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T. N., Cella, D. F., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,104
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,640
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G. A., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,639
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,594
Self-citation
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Pàez‐Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,373
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Tumor Angiogenesis
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 2,011
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,985
Self-citation
AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Self-citation
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz‐Muñoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,739
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,630
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,600
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,047
Self-citation
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S., Archer, L. E., Atkins, J. N., Picus, J., Czaykowski, P. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9847 · Cited by 894
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Relf, M., LeJeune, S., Scott, P. A. E., Fox, S. B., Smith, K. A., Leek, R., Moghaddam, A., Whitehouse, R. M., Bicknell, R., & Harris, A. L. (1997) · PubMed · Cited by 833
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., Mol, M. D., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 780
Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
Schneider, B. P., Wang, Μ., Radovich, M., Sledge, G. W., Badve, S., Thor, A. D., Flockhart, D. A., Hancock, B. A., Davidson, N. E., Gralow, J. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Hamzah, J., Jugold, M., Kiessling, F. M., Rigby, P. J., Manzur, M., Marti, H. H., Rabie, T., Kaden, S., Gröne, H., Hämmerling, G. J., et al. (2008) · Nature · doi:10.1038/nature06868 · Cited by 565
REporting recommendations for tumor MARKer prognostic studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0252 · Cited by 563
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
Willett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 509
Self-citation
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Zhu, A. X., Sahani, D. V., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Catalano, O. A., Sindhwani, V., Blaszkowsky, L. S., Yoon, S. S., Lahdenranta, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9908 · Cited by 479
Self-citation
Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients
Willett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5635 · Cited by 420
Self-citation
Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b
Yao, J. C., Phan, A. T., Hoff, P. M., Chen, H. X., Charnsangavej, C., Yeung, S. J., Hess, K. R., Ng, C. S., Abbruzzese, J. L., & Ajani, J. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6374 · Cited by 415
Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
Loges, S., Mazzone, M., Hohensinner, P. J., & Carmeliet, P. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.007 · Cited by 400
A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
Sorensen, A. G., Batchelor, T. T., Zhang, W., Chen, P.-J., Yeo, P., Wang, M., Jennings, D. L., Wen, P. Y., Lahdenranta, J., Ancukiewicz, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0814 · Cited by 395
Self-citation
Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
Rini, B. I., Michaelson, M. D., Rosenberg, J. E., Bukowski, R. M., Sosman, J. A., Stadler, W. M., Hutson, T. E., Margolin, K. A., Harmon, C. S., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5416 · Cited by 393
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
Chen, W., Delaloye, S., Silverman, D. H. S., Geist, C. L., Czernin, J. G., Sayre, J. W., Satyamurthy, N., Pope, W. B., Lai, A., Phelps, M. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5825 · Cited by 391
Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer
Jubb, A. M., Hurwitz, H. I., Bai, W., Holmgren, E. B., Tobin, P., Guerrero, A., Kabbinavar, F. F., Holden, S. N., Novotny, W. F., Frantz, G. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5388 · Cited by 390
Technology Insight: water diffusion MRI—a potential new biomarker of response to cancer therapy
Patterson, D. M., Padhani, A. R., & Collins, D. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1073 · Cited by 370
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 368
Key factors in the acquisition of contrast kinetic data for oncology
Evelhoch, J. L. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3 · Cited by 366
Prognostic versus predictive value of biomarkers in oncology
Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A., & de Vries, E. G. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.006 · Cited by 349
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
DePrimo, S. E., Bello, C. L., Smeraglia, J., Baum, C. M., Spinella, D. G., Rini, B. I., Michaelson, M. D., & Motzer, R. J. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-32 · Cited by 319
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F. F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 318
Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
Kamoun, W. S., Ley, C. D., Farrar, C. T., Duyverman, A. M., Lahdenranta, J., Lacorre, D. A., Batchelor, T. T., di Tomaso, E., Duda, D. G., Munn, L. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9356 · Cited by 309
Self-citation
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
Drevs, J., Siegert, P., Medinger, M., Mross, K. B., Strecker, R., Zirrgiebel, U., Harder, J., Blum, H. E., Robertson, J. D., Jürgensmeier, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2066 · Cited by 303
Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival
Hamstra, D. A., Galbán, C. J., Meyer, C. R., Johnson, T. D., Sundgren, P. C., Tsien, C. I., Lawrence, T. S., Junck, L., Ross, D. J., Rehemtulla, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2363 · Cited by 282
Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study
Dowlati, A., Gray, R. J., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1154 · Cited by 264
Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study
Liu, G., Rugo, H. S., Wilding, G., McShane, T. M., Evelhoch, J. L., Ng, C. S., Jackson, E. F., Kelcz, F., Yeh, B. M., Lee, F. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.143 · Cited by 260
Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer
Thomas, A., Morgan, B., Horsfield, M. A., Higginson, A., Kay, A., Lee, L., Masson, E., Puccio-Pick, M., Laurent, D., & Steward, W. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.034 · Cited by 228
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
Motzer, R. J., Bukowski, R. M., Figlin, R. A., Hutson, T. E., Michaelson, M. D., Kim, S. T., Baum, C. M., & Kattan, M. W. (2008) · Cancer · doi:10.1002/cncr.23776 · Cited by 211
Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells.
Yoshiji, H., Harris, S. R., & Thorgeirsson, U. P. (1997) · PubMed · Cited by 204
Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor
Norden-Zfoni, A., Desai, J., Manola, J. B., Beaudry, P., Force, J. M., Maki, R. G., Folkman, J., Bello, C. L., Baum, C. M., DePrimo, S. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0919 · Cited by 199
Response criteria for glioma
Sorensen, A. G., Batchelor, T. T., Wen, P. Y., Zhang, W., & Jain, R. K. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1204 · Cited by 191
Self-citation
Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
Schultheis, A. M., Lurje, G., Rhodes, K. E., Zhang, W., Yang, D., García, A. A., Morgan, R. J., Gandara, D. R., Scudder, S., Oza, A. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0351 · Cited by 182
Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer
Jain, R. K. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2346 · Cited by 167
Self-citation
Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma
Zhu, A. X., Holalkere, N.-S., Muzikansky, A., Horgan, K. E., & Sahani, D. V. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0174 · Cited by 161
Self-citation
Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer
Crabb, S. J., Patsios, D., Sauerbrei, E. E., Ellis, P. M., Arnold, A., Goss, G. D., Leighl, N. B., Shepherd, F. A., Powers, J., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2545 · Cited by 159
Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab
Sandler, A. B., Schiller, J. H., Gray, R. J., Dimery, I. W., Brahmer, J. R., Samant, M. K., Wang, L. I., & Johnson, D. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2412 · Cited by 154
Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy
Saltz, L. B., Rosen, L. S., Marshall, J. L., Belt, R. J., Hurwitz, H. I., Eckhardt, S., Bergsland, E. K., Haller, D. G., Lockhart, A. C., Lima, C. M. R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.8637 · Cited by 141
VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy
Burstein, H. J., Chen, Y., Parker, L. M., Savoie, J., Younger, J., Kuter, I., Ryan, P. D., Garber, J. E., Chen, H., Campos, S. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0593 · Cited by 139
Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma
de BAZELAIRE, C., Alsop, D. C., George, D. J., Pedrosa, I., Wang, Y., Michaelson, M. D., & Rofsky, N. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0417 · Cited by 113
Platelets Take Up the Monoclonal Antibody Bevacizumab
Verheul, H. M. W., Lolkema, M. P., Qian, D. Z., Hilkes, Y. H. A., Liapi, E. A., Akkerman, J. N., Пили, Р., & Voest, E. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0847 · Cited by 112
Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736)
Rini, B. I., Schiller, J. H., Fruehauf, J. P., Cohen, E. E. W., Tarazi, J., Rosbrook, B., Ricart, A. D., Olszanski, A. J., Kim, S., & Spano, J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3543 · Cited by 93
Magnetic Resonance As a Cancer Imaging Biomarker
Sorensen, A. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6597 · Cited by 79
Self-citation
Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer
Cameron, D., & Stein, S. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1156 · Cited by 75
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma
Mita, M. M., Rowinsky, E. K., Forero, L., Eckhart, S. G., Izbicka, E., Weiss, G. R., Beeram, M., Mita, A. C., Bono, J. S. D., Tolcher, A. W., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0255-0 · Cited by 49
Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo
Köhne, C.-H., Bajetta, E., Lin, E. H., Valle, J. W., Cutsem, E. V., Hecht, J. R., Moore, M., Germond, C. J., Meinhardt, G., & Jacques, C. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4033 · Cited by 47
Expensive Cancer Drugs With Modest Benefit Ignite Debate Over Solutions
Sinha, G. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn357 · Cited by 18
Novel risk-sharing scheme puts the spotlight on biomarkers
Hughes, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2478 · Cited by 16
A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis
Tannir, N. M., Zurita, A. J., Heymach, J. V., Tran, H., Pagliaro, L. C., Corn, P. G., Aparicio, A. M., Ashe, R., Wright, J. R., & Jonasch, E. W. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5093 · Cited by 13
Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Duda, D. G., Zhang, W., Ancukiewicz, M., Lahdenranta, J., Louis, D. N., Plotkin, S. R., Ivy, P. S., et al. (2008) · Cancer Research · doi:10.1158/1538-7445.am2008-lb-247 · Cited by 12
Self-citation
Use of intratumoral mRNA expression of genes involved in angiogenesis and HIF1 pathway to predict outcome to VEGFR tyrosine kinase inhibitor (TKI) in patients enrolled in CONFIRM1 and CONFIRM2
Wilson, P. M., Yang, D., Shi, M., Zhang, W., Jacques, C. J., Barrett, J. C., Daneneberg, K., Trarbach, T., Folprecht, G., Meinhardt, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4002 · Cited by 10
Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC
Heymach, J. V., Hanrahan, E. O., Mann, H., Langmuir, P. B., Natale, R. B., Johnson, B. E., Herbst, R. S., & Ryan, A. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8009 · Cited by 10
A comparative study of circulating endothelial cells (CECs) and circulating progenitor cells (CPCs) kinetics in four multidisciplinary phase II studies of antiangiogenic agents
Duda, D. G., Cohen, K. S., Ancukiewicz, M., di Tomaso, E., Zhu, A., Penson, R. T., Horowitz, N. S., Batchelor, T. T., Willett, C. G., & Jain, R. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3544 · Cited by 8
Self-citation

Flagged first, then by citations

1 of the 83 references couldn’t be matched to a known paper.

Sorted by citations

Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citation
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citation
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,762
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Self-citation

See all 573

Authors: Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G.
Affiliations: Harvard University (US)
Duke Medical Center (US)
Corresponding author: Jain, Rakesh K.
ORCID: Duda, Dan G.
Willett, Christopher G.
Zhu, Andrew X.
Batchelor, Tracy T.
Sorensen, A. Gregory
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2009-06
Volume: 6
Issue: 6
Pages: 327-338
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2009.63
PMC: PMC3057433
OpenAlex: W1993016882
Cited by: 572
References: 83
Citations by year: 2026: 10 · 2025: 14 · 2024: 9 · 2023: 15 · 2022: 11 · 2021: 19 · 2020: 26 · 2019: 17 · 2018: 25 · 2017: 33 · 2016: 35 · 2015: 38 · 2014: 44 · 2013: 57 · 2012: 67
FWCI: 5.58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA115767, R01CA57683, R01 CA 85140, R21CA117079, R01CA085140, R01CA057683, R21-CA 99237, P01CA080124, R21CA099237, R01CA126642, K24CA125440, R01CA129371, P01-CA-80124)
National Center for Research Resources (P41-RR-14075, M01RR001066, P41RR014075, M01-RR01066)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: anti-angiogenic therapy, biomarkers, treatment response, drug resistance, patient selection, VEGF polymorphisms, type IV collagen, pharmacodynamic biomarkers, imaging biomarkers, Ktrans, placental growth factor, stromal cell-derived factor-1α, interleukin-6, tumor stroma
MeSH terms: Humans, Neoplasms, Neovascularization, Pathologic, Biomarkers, Tumor, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Biomarkers of response and resistance to antiangiogenic therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks